MétaCan
Menu
Back to cohort
Record W4407778998 · doi:10.3390/jcm14051416

Psychedelics and Suicide-Related Outcomes: A Systematic Review

2025· review· en· W4407778998 on OpenAlexafffund
Shakila Meshkat, Taha Malik, Richard J. Zeifman, Jennifer Swainson, Yanbo Zhang, Lisa Burback, Olga Winkler, Andrew J. Greenshaw, Amy C. Reichelt, Eric Vermetten, David Erritzøe, Manish K. Jha, Walter Dunn, Rakesh Jetly, Muhammad Ishrat Husain, Venkat Bhat

Bibliographic record

VenueJournal of Clinical Medicine · 2025
Typereview
Languageen
FieldPsychology
TopicPsychedelics and Drug Studies
Canadian institutionsUniversity of TorontoCentre for Addiction and Mental HealthWomen and Children’s Health Research InstituteUniversity of OttawaSt. Michael's HospitalWestern UniversityUniversity of Alberta
FundersJanssen Research and DevelopmentCanadian Institutes of Health ResearchMinistère de la Défense NationaleBausch HealthNovo NordiskACADIA PharmaceuticalsEisaiIdorsia PharmaceuticalsRoyal College of Physicians and Surgeons of CanadaUniversity of TorontoAssociated Medical ServicesH. Lundbeck A/SGovernment of CanadaAmerican Foundation for Suicide PreventionJanssen Scientific Affairs
KeywordsMedicinePsilocybinSuicidal ideationMDMAOdds ratioPsycINFORandomized controlled trialPoison controlPsychiatryMeta-analysisHallucinogenSuicide preventionMEDLINEInternal medicineEmergency medicine

Abstract

fetched live from OpenAlex

Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscores the need for alternatives. Psychedelic therapies may rapidly reduce suicide risk. This systematic review evaluates impact of psychedelic therapies on suicide-related outcomes. Methods: A systematic search of MEDLINE, Embase, PsycINFO, and ClinicalTrials.gov was conducted up to November 2024. Results: Four randomized controlled trials (RCTs) evaluated suicidality as a secondary outcome or safety measure, showing significant reductions in suicidal ideation with psilocybin (three studies) and MDMA-assisted therapy (MDMA-AT; one study). Effect sizes, measured by Cohen’s d, ranged from =0.52 to 1.25 (p = 0.01 to 0.005), with no safety issues reported. Five additional RCTs assessed suicidality as a safety measure, showing reductions in suicidal ideation with psilocybin (two studies) and MDMA-AT (three studies; p = 0.02 to 0.04). Among 24 non-randomized and cross-sectional studies, results were mixed. Psilocybin (three studies) reduced suicidal ideation, with odds ratios (OR) of 0.40–0.75. MDMA-AT (five studies in PTSD patients) had a pooled effect size of d = 0.61 (95% CI: 0.32–0.89). LSD (six studies) showed increased odds of suicidality, with odds ratios ranging from 1.15 to 2.08. Studies involving DMT (two studies) and multiple psychedelics (three studies) showed mixed results, with DMT studies not showing significant effects on suicidality and studies involving multiple psychedelics showing varying outcomes, some reporting reductions in suicidal ideation and others showing no significant change. Conclusions: The effect of psychedelic therapies on suicide-related outcomes remains inconclusive, highlighting the need for further trials to clarify safety and therapeutic mechanisms.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.025
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow), Meta-epidemiology (broad)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.264
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0120.025
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0170.002
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.261
GPT teacher head0.608
Teacher spread0.347 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical MedicineSame topicPsychedelics and Drug StudiesFrench-language works237,207